Colloids (Blood Plasma) Market

Global Statistics Representing Colloids (Blood Plasma) Market Scenario

Colloids (blood plasma) can be defined as the liquid component of whole blood, comprising up to 60% of total blood volume, which contains proteins such as serum fibrinogen, albumins, and globulins. Other factors present in blood plasma include clotting factors, glucose, hormones, mineral ions, and carbon dioxide, which enable the use of blood plasma in the treatment of excessive bleeding and other blood related diseases such as gastrointestinal bleeding and hepatitis B virus infection.

Increasing prevalence of chronic and severe diseases around the globe is expected to drive the market in the next few years. According to the Centers for Disease Control & Prevention (CDC), 6 in every 10 adults in America are suffering through chronic diseases and 4 in every 10 adults have 2 or more chronic diseases. Further stated, heart diseases, cancers, chronic lung diseases, and chronic kidney diseases, are some of the chronic diseases which are the leading causes of death in North America. Moreover, rising number of severe diseases in low to middle income countries across the globe is expected to support the market growth.

Increasing prevalence of chronic gastrointestinal bleeding disorders, rising incidences of liver diseases and disorders, and growing number of accidents across the globe resulting in extensive blood loss are some of the factors notably increasing the demand for colloids (blood plasma). According to the National Institute of Diabetes & Digestive and Kidney Diseases, more than 100,000 people suffer from gastrointestinal tract bleeding disorders in the U.S. Colloids (blood plasma) treatment recovers blood and blood plasma volume in the body after heavy blood loss, and thus, the demand for natural and synthetic blood plasma has been increasing. China imported more than 60% of its total blood plasma consumption from the U.S. in 2016 and the demand has been increasing by 15% annually since then. High prevalence of hepatitis B virus in Asian countries is expected to upsurge the demand for blood plasma for effective treatments.

Global Colloids (Blood Plasma) market is expected to reach USD 3,868 million in 2026 from USD 2,568.9 million in 2018 at a CAGR of 5.3% during the forecast period 2019–2026

Segmental Insights

Global colloids (blood plasma) market is segmented into type, application, and region.

Based on type, the market is segmented into natural type colloids and synthetic type colloids. Natural type colloids consist of water and proteins such as fibrinogen, globulins, and serum albumins. Natural plasma is preferred for the treatment of people suffering from shock, burns, trauma, liver diseases, and hepatitis B virus infection. Rising awareness regarding the benefits of blood donation in increasing production of colloids (blood plasma) and increasing prevalence of hepatitis B virus infection in developing regions including Asia Pacific and Africa, are some of the key factors driving the growth of the natural type colloid segment. Synthetic type colloids are derived from fluorine and carbon containing chemicals that are chemically inert in nature and highly effective in dissolving, absorbing, and transporting oxygen in lungs and throughout the body. The robust nature of synthetic blood plasma and its quality of surviving harsh environments such as no-refrigeration and pre-hospital are expected to drive the growth of the synthetic type colloids segment.

Regional Insights

Based on region, the market is segmented into North America, Europe, Asia Pacific (APAC), and South America and the Middle East & Africa.

North America dominates the global colloids (blood plasma) market. Increasing incidences of people suffering from burns, especially over the past few years, have been contributing to the growth of the colloids market in North America. According to the National Burn Repository (NBR) of the American Burn Association (ABA), in 2016, more than 486,000 burn injuries were recorded in the U.S., which received medical treatment for severe burns. High effectiveness of blood plasma treatment in severe burn injuries and growing awareness regarding the treatment are projected to bolster market growth in the future. The prevalence of liver disorders among Chinese patients is providing impetus to the import of human serum albumin from the U.S., with a consumption of 300 tons of human serum albumin in 2016. In 2016, 60% of the total consumed human serum albumin in China was imported from the U.S., which has positively influenced the North America colloids market.

Europe accounts for optimum share of the global market. The steady rise in the number of injuries resulting in blood loss is driving the Europe colloids (blood plasma) market. According to the Annual Accident Report of the European Road Safety Observatory, the number of injuries due to accidents resulting in heavy blood loss increased in Europe from around 1.39 million in 2013 to 1.48 million in 2016. Rapid recovery of blood plasma volume due to colloid treatment and increasing number of colloid manufacturers in the region are further aiding market growth.

Key Players

Some of the major players of the global colloids (blood plasma) market are, CSL Behring, Baxter, Grifols, S.A., Octapharma, Shanghai RAAS Blood Products Co., Ltd., Shandong Taibang Biological Products Co. Ltd (China Biologic Products, Inc.), Hualan Biological Engineering Inc., Chengdu Rongsheng Pharmaceuticals Co., Ltd. (China National Pharmaceutical Group Corporation), and Adma Biologics Inc.

Colloids (Blood Plasma) Market Segmentation

By Type

• Natural Type Colloids
• Synthetic Type Colloids

By Application

• Extensive Burns
• Massive Blood or Plasma Loss
• Hypovolemic Shock

By Region

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa